TECHNOLOGY
By acting as a marker on tumor cells, EBV also presents an opportunity for targeted treatment—one that BioSyngen is on a mission to exploit.
Nasopharyngeal cancer rates are highest in Asia, with the region accounting for 70 percent of the global patient population. Prognosis remains poor and the overall survival is less than 12 months for relapsed/ metastatic cases
From Hodgkin’s lymphoma to extranodal NK/T lymphoma, EBV contributes to ~40 percent of total lymphoma cases.
Chronic hepatitis B virus (HBV) infection accounts for at least 50% cases of hepatocellular carcinoma worldwide. In Asia, it is the third leading cause of cancer mortality, urgently needing next-generation cell therapies to improve clinical outcomes.
Over a million new colorectal cancer cases are recorded each year worldwide, with the disease burden steadily rising in Asia. As standard interventions are limited to surgery and chemo- or radiotherapy, immunotherapies targeting solid tumors can potentially provide patients with better options
Gastric cancer is the second leading cause of cancer-related deaths globally and is much more common in Asian populations. EBV+ cases show unique genomic alterations and pathological features that immunotherapies can potentially target.
PLATFORM
To develop immunotherapies for virus-related cancers, the BioSyngen approach is anchored on world’s largest EBV-specific library, for which we own the exclusive intellectual property. This extensive resource is our first differentiator; we are one of the few CAR-T projects for virus-related cancers and focus on highly prevalent EBV antigens as our main target.
Our library contains molecular data on EBV expression profiles, the corresponding receptors, and their underlying genetic sequence—including differences among cancer subtypes and various populations such as Asian and Caucasian groups.
PLATFORM
Our unique platform for antigen/TCR/Ab identification
Our dual-targeting T cells with intracellular signal modification, for broader coverage of tumor cell population while ensuring the safety at the same time
Short for multiple signal enhanced T cell, our proprietary next gen CAR-T and TCR-T therapy to equip T cell with additional functional domains for better solid tumor targeting
To develop immunotherapies for virus-linked cancers, the BioSyngen approach is anchored on world’s largest EBV-specific library, for which we own the exclusive intellectual property.
This extensive resource is our first differentiator; we are one of the few groups worldwide utilizing CAR/TCR-T for virus-linked cancers and focus on highly prevalent EBV antigens as our main target
Synthesizing this wealth of information, our platform reengineers patient-derived T cells to express the TCR or CAR. Our GMP production facilities further expand the T cell army through state-of-the-art culturing methods.
When infused into the patient, the highly specific receptors enable detection and binding to the cancer cell, while importantly reducing the “on-target, off-tumor” toxicities that typically plague other immunotherapies. Taken together, this significantly boosts the clinical efficacy, reliability, and safety of BioSyngen therapeutics.
Compared to the thousands of CAR-T cell projects that already target liquid cancers, our approach stands out by addressing difficult-to-treat solid tumors—challenging the limits and expanding the scope of immunotherapy applications. As our library also contains patient HLA data, BioSyngen therapies can match with and serve a broader range of individuals, enabling the T cells to survive in the tumor microenvironment for long enough to recognize and lyse the cancer cells.
Moreover, other immune cells are recruited to generate a stronger anti-tumor response and offer better protection against any potential relapse.
HIGHLIGHTS
BioSyngen’s patented CAR-T cell therapy is the first-of-its-kind against virus-related solid cancers, targeting EBV antigens and filling a critical gap in immuno-oncology.
Rooted in a patient-centric approach, BioSyngen generates highly potent immunotherapies that are fit for each individual and carry enhanced safety profiles.
Copyright © 2022
Biosyngen Pte. Ltd.
Copyright © 2022 Biosyngen Pte. Ltd.
MENU
